



FORENSIC TESTING PROGRAM

Manufacturer's Information
Test No. 10-572: Forensic Biology

Each sample pack consisted of two known bloodstains on FTA Genecards (Items 1 & 2), and two questioned stains one on clean, dark green material (Item 3) and one on clean, blue material with dark blue flowers (Item 4). The stains in all four Items were prepared from human whole blood which was drawn into citric acid preservative bloodbank bags. Items 1 and 3 were blood collected from one female donor and Items 2 and 4 were blood collected from one male donor. Stains from different sources were prepared on separate days and were packaged once they were thoroughly dried.

Sample Preparation Schedule				
<u>Item</u>	<u>Sample Collected</u>	<u>Prepared</u>	<u>Packaged</u>	<u>Volume</u>
1	January 5, 2010	January 28, 2010	January 28, 2010	75 µl
2	January 5, 2010	January 29, 2010	January 29, 2010	75 µl
3	January 5, 2010	January 15, 2010	January 18, 2010	50 µl
4	January 5, 2010	January 14, 2010	January 15, 2010	50 µl

Completed sample sets were stored at -20°C until shipment on March 2, 2010 following receipt of predistribution results.

Amelogenin and STR Results								
<i>Results compiled from predistribution laboratories and a consensus of at least 10 participants.</i>								
<u>Item</u>	<u>D3S1358</u>	<u>D5S818</u>	<u>D7S820</u>	<u>D8S1179</u>	<u>D13S317</u>	<u>D16S539</u>	<u>D18S51</u>	<u>D21S11</u>
1	15,16	10,12	9,9	9,14	11,12	11,13	13,15	28,31
2	15,18	12,13	10,11	9,15	9,11	11,13	10,12	31,32.2
3	15,16	10,12	9,9	9,14	11,12	11,13	13,15	28,31
4	15,18	12,13	10,11	9,15	9,11	11,13	10,12	31,32.2
<u>Item</u>	<u>Amel</u>	<u>CSF1PO</u>	<u>FGA</u>	<u>TH01</u>	<u>TPOX</u>	<u>vWA</u>	<u>Penta D</u>	<u>Penta E</u>
1	X,X	10,11	20,24	7,9.3	8,11	15,18	13,15	8,8
2	X,Y	10,12	20,20	7,9	8,11	17,17	9,12	17,17
3	X,X	10,11	20,24	7,9.3	8,11	15,18	13,15	8,8
4	X,Y	10,12	20,20	7,9	8,11	17,17	9,12	17,17
<u>Item</u>	<u>D2S1338</u>	<u>D19S433</u>						
1	19,22	12,12						
2	15,23	14,14.2						
3	19,22	12,12						
4	15,23	14,14.2						

YSTR and Mitochondrial results on next page.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.

Manufacturer's Information, continued
Test No. 10-572: Forensic Biology

YSTR Results										
<i>Results compiled from predistribution laboratories and a consensus of at least 10 participants.</i>										
<u>Item</u>			<u>DYS19</u>	<u>DYS385</u>	<u>DYS389-I</u>	<u>DYS389-II</u>	<u>DYS390</u>	<u>DYS391</u>		
2			15	14,15	13	31	23	10		
4			15	14,15	13	31	23	10		
<u>Item</u>	<u>DYS392</u>	<u>DYS393</u>	<u>DYS437</u>	<u>DYS438</u>	<u>DYS439</u>	<u>DYS448</u>	<u>DYS456</u>	<u>DYS458</u>	<u>DYS635</u>	<u>YGATAH4</u>
2	12	14	14	10	11	20	14	14	21	12
4	12	14	14	10	11	20	14	14	21	12

Mitochondrial DNA Sequencing Results										
Bases Sequenced	<i>The following is the overall range of bases sequenced for each Item, as compiled from predistribution laboratories and a consensus of at least 10 participants.</i>									
<u>Item</u>	<u>HVR-I</u>					<u>HVR-II</u>				
1	15994-16569					1-576				
2	15994-16569					1-576				
3	15994-16405					35-409				
4	15994-16400					35-409				

HVR I Region										
	16124.0	16126.0	16189.0	16223.0	16274.0	16278.0	16286.0	16294.0	16304.0	16362.0
ITEM 1	C		C	T		T				C
ITEM 2		C			A		T	T	C	
ITEM 3	C		C	T		T				C
ITEM 4		C			A		T	T	C	
HVR II Region										
	73.0	152.0	263.0	309.1	315.1	385.0				
ITEM 1	G	C	G	Cins.	Cins.					
ITEM 2	G		G	Cins.	Cins.	G				
ITEM 3	G	C	G	Cins.	Cins.					
ITEM 4	G		G	Cins.	Cins.	G				

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.